24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
NCT: NCT06689696 · COMPLETED
Brief Summary
The goal of this clinical trial is to learn if a new contact lens device can record patterns in eye pressure for 24 hours in adults with glaucoma and in healthy participants. The main questions it aims to answer are: * Is the contact lens device able to detect patterns in eye pressure that happens naturally between nighttime and daytime? * Are the contact lens recording patterns similar when repeated one week later? * What eye problems do participants have when wearing contact lens for up to 24 hours? Researchers will compare if the recordings detected by the contact lens over 24 hours are similar to the patterns measured by an eye pressure measuring instrument used in a doctor's office. Participants will * Wear contact lens in one eye for up to 24 hours * Take recordings in that eye with smartphone camera every 15 minutes when awake * For those participants who are able to stay overnight at a hotel for the trial, researchers will measure the eye pressure in the other eye every 1 to 2 hours when awake with an eye pressure measuring instrument.
Frequently Asked Questions
What is 24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring?
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring is a clinical trial registered under NCT06689696. Current status: COMPLETED.
What is the status of NCT06689696?
The current status of NCT06689696 (24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring) is: COMPLETED.
When did 24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring start?
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring started on 2025-02-19.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.